Equities

BIO

PLBIOTN00029

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:40 2024-04-29 am EDT			5-day change	1st Jan Change
3.505 ^PLN	0.00%		-0.43%	-1.82%

Mar. 28	BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Current report 4/2017 dated 28.03.2017, time 18:37 UTC

March 29, 2017 at 05:19 am EDT

Current report no: 4/2017 Date: 2017-03-28 Change of the date of publication of standalone annual report and consolidated annual report for 2016

BIOTON S.A. ("Company") informs about a change of the date of publication of the Company's standalone annual report and consolidated annual report for 2016 from 31.03.2017 to 14.04.2017.

Bioton SA published this content on 28 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 29 March 2017 09:19:12 UTC.

Public permalinkhttp://www.publicnow.com/view/2D44C4046814324E55B937924273887D4A1C7BF7

Latest news about BIOTON S.A.

BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
BIOTON S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
BIOTON S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
BIOTON S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
BIOTON S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-29	CI
Bioton S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
Bioton S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-30	CI
Yifan Pharmaceutical Co., Ltd. completed the acquisition of 19.79% stake in BIOTON S.A. from Ningbo Free Trade Zone Dongren Investment Co., Ltd.	19-10-29	CI
Yifan Pharmaceutical Co., Ltd. completed the acquisition of 11.86% stake in BIOTON S.A. from Kelipond Investment Limited.	19-10-29	CI
Yifan Pharmaceutical Co., Ltd. signed an agreement to acquire 11.86% stake in BIOTON S.A. from Kelipond Investment Limited for approximately CNY 270 million.	19-09-02	CI
Yifan Pharmaceutical Co., Ltd. agreed to acquire 19.79% stake in BIOTON S.A. from Ningbo Free Trade Zone Dongren Investment Co., Ltd. for approximately CNY 450 million.	19-09-02	CI
YiFan International Pharmaceutical Co., Limited completed the acquisition of SciGen Ltd from BIOTON S.A. and others.	18-08-06	CI
YiFan International Pharmaceutical Co., Limited made a pre conditional offer to acquire SciGen Ltd from BIOTON S.A. and others for $28 million.	18-05-15	CI
BIOTON Seeks Investor For SciGen Stake	17-12-13	CI
Medwise Pharmaceuticals Limited completed the acquisition of Tricel S.A. from BIOTON S.A..	17-12-02	CI
BIOTON S.A.(WSE:BIO) dropped from S&P Global BMI Index	17-09-18	CI
BIOTON S.A. signed a preliminary agreement to acquire Tricel S.A. from BIOTON S.A..	17-04-23	CI
Marvel Bioscience Limited completed the acquisition of an additional 50% stake in M.J. Bioton Life Sciences Ltd. from BIOTON S.A..	16-12-30	CI
Perfect Trend Ventures Limited acquired 9.99% stake in BIOTON S.A..	16-12-04	CI
Bioton S.A. Reports Consolidated and Company Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-26	CI
Marvel Bioscience Limited signed an agreement to acquire an additional 50% stake in M.J. Bioton Life Sciences Ltd. from BIOTON S.A. for $6 million.	16-08-30	CI

Chart BIOTON S.A.

Duration

Period

More charts

Company Profile

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTON S.A.	-1.82%	74.34M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs